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Parkinson’s disease is a condition that has been 
known about since ancient times. It is referred to in 
the ancient Indian medical system of Ayurveda under 
the name Kampavata. However, it was not until 1817 
that a detailed medical essay: “An Essay on the Shak-
ing Palsy” published by James Parkinson fi rst formally 
described the disease in modern times. About 60 years 
after the essay was published, a French neurologist 
Jean Martin Charcot recognized the importance of 
Parkinson’s work and named the disease after him in 
early 1860s. In 1867 Charcot introduced a treatment 
with the alkaloid drug hyoscine (or scopolamine) de-
rived from the Datura plant, an anticholinergic drug. 
Anticholinergic drugs are still used in treatment of 
Parkinson’s disease even today.
In the 1950s, Arvid Carlsson demonstrated that 
dopamine was a neurotransmitter in the brain and not 
just a precursor for norepinephrine, as had been previ-
ously believed. He found that dopamine levels in the 
basal ganglia were particularly high. He then showed 
that giving animals the drug reserpine caused a de-
crease in dopamine levels and a loss of movement con-
trol, the eff ects similar to the symptoms of Parkinson’s 
disease. Arvid Carlsson subsequently won the Nobel 
Prize in Physiology or Medicine in 2000 along with 
co-recipients Eric Kandel and Paul Greengard.
In 1961, levodopa was fi rst tried in PD patients, but 
throughout most of the 1960s the results were incon-
sistent. In 1967, questions about the eff ectiveness of 
levodopa in PD were fi nally set aside when Cotzias and 
colleagues reported dramatic improvement in PD pa-
tients with oral administration of levodopa in increas-
ing amounts over long periods. Th e fi rst study report-
ing improvements in patients with Parkinson’s disease 
resulting from treatment with L-dopa was published in 
1968, and levodopa therapy become the standard treat-
ment for Parkinson’s disease. Even today levodopa is 
the “gold standard” for Parkinson’s disease therapy, and 
it has even some diagnostic value, i.e. if a patient does 
not respond to levodopa therapy, most probably he does 
not have idiopathic Parkinson’s disease.
In the early 1970s, the advantages of adding a dopa 
decarboxylase inhibitor to treatment were discovered-
reducing side eff ects and gaining better symptom con-
trol, and the fi rst levodopa combinations, carbidopa/
levodopa, and benserazide/levodopa, became com-
mercially available in mid 1970s. Afterwards, long-
acting, slow-release and continuous-release levodopa 
combinations became available.
A dopamine agonist, apomorphine, was used in 
1970 as a means to overcome side eff ects and loss of 
levodopa effi  cacy. However, side eff ects and diffi  culty 
of administration limited its use. Dopamine agonists 
began to fi nd a place in routine treatment of PD af-
ter the discovery of bromocriptine’s benefi ts in PD in 
1974. Afterwards the other dopaminergic drugs also 
became available, esspecially non-ergot dopaminergic 
agents such as ropinirole and pamipexole.
Selegiline was discovered in Hungary in the 
1960s. Th e fi rst publication on selegiline in Hungar-
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ian appeared in 1964, followed by a paper in English 
in 1965. In 1971 it was shown that selegiline selec-
tively inhibits the B-isoform of monoamine oxidase 
(MAO-B), and a few years later it was realized that 
selegiline could be useful in Parkinson’s disease. Since 
then selegiline is used in pharmacotherapy of Parkin-
son’s disease either as a monotherapy in early stages, 
or as add-on therapy in later stages of disease. In re-
cent years, a new MAO-B inhibitor, rasagiline, was 
introduced in Parkinson’s disease therapy.
Amantadine was approved by the U.S. Food and 
Drug Administration in 1966 as a prophylactic agent 
against Asian infl uenza. However, in 1969, by acci-
dent it was discovered that amantadine help reduce 
symptoms of Parkinson’s disease, and it is used in 
early stages of Parkinson’s disease, and for temporary 
alleviation of levodopa induce dyskinesias.
In late 1990s catechol-O-methyltransferase 
(COMT) inhibitors: tolcapone and entacapone have 
been approved for treatment of Parkinson’s disease, 
mainly as an adjunctive therapy to levodopa. Later, 
tolcapone was removed because of liver toxicity.
In the 1940s and 1950s, neurosurgeons began 
to perform surgery on the basal ganglia of the brain 
that resulted in improvements in Parkinson’s disease 
symptoms. Th is surgery was eff ective, but it was risky, 
with high percent of patients dying as a result of the 
operation. On the other hand, with introduction of 
levodopa in therapy, the enthusiasm for neurosurgi-
cal approach temporarily vanished. However, because 
of the problems associated with long-term levodopa 
treatment, in the eighties and nineties, the surgical 
approach was once again investigated. Various neuro-
surgical procedures were tested, mostly destruction of 
the ventrolateral part of the thalamic nucleus – thala-
motomy, or of the globus pallidus – pallidotomy. Pal-
lidotomy became very popular, until it became obvi-
ous that good postoperative eff ects did not last long, 
so it was mainly abandoned. In recent years deep brain 
stimulation (DBS) is used. It uses small programma-
ble implanted electrodes surgically inserted into the 
thalamus, pallidum or subthalamic structures.
Diagnosis of Parkinson’s disease is still based on 
clinical ground. However, in recent years single photon 
emission tomography (SPECT) and positron emis-
sion tomography (PET) using special radiotracers are 
used for confi rmation of Parkinson’s disease diagnosis 
showing reduced striatal radiotracer uptake. Tran-
scranial sonography of brain parenchyma showing the 
hyperechogenicity of substantia nigra is also used in 
diagnosis of Parkinson’s disease. A number of specifi c 
genetic mutations causing rare familial forms of Par-
kinson’s disease have been discovered.
In the last fi fty years we witnessed huge progress 
in Parkinson’s disease. Many projects are underway 
researching new possibilities in etiology, pathogen-
esis,  genetics, diagnosis and treatment of Parkinson’s 
disease. Th erefore, the outlook for Parkinson’s disease 
look bright.
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